Silo Pharma, Inc. (SILO)
(Delayed Data from NSDQ)
$1.09 USD
-0.01 (-0.91%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $1.09 +0.01 (0.46%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Silo Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 4 | 4 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -4 | -4 | -3 | -3 | -1 |
Non-Operating Income | 0 | 0 | 7 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -4 | -4 | 4 | -3 | -1 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -4 | 4 | -3 | -1 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -4 | 4 | -3 | -1 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -4 | -4 | -3 | -2 | -1 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 1 | 0 |
Income After Depreciation & Amortization | -4 | -4 | -3 | -3 | -1 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3.08 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.18 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -1.20 | -1.71 | 0.04 | -0.05 | -0.04 |
Fiscal Year end for Silo Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
SG&A, R&D, and Dept/Amort Expenses | 1.02 | 0.90 | 1.18 | 0.79 | 1.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -1.00 | -0.88 | -1.16 | -0.77 | -1.11 |
Non-Operating Income | 0.07 | 0.08 | 0.11 | 0.11 | 0.10 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -0.93 | -0.80 | -1.05 | -0.66 | -1.01 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -0.93 | -0.80 | -1.05 | -0.66 | -1.01 |
Extras & Discontinued Operations | 0.00 | 0.00 | -0.07 | 0.00 | 0.00 |
Net Income (GAAP) | -0.93 | -0.80 | -1.12 | -0.66 | -1.01 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.05 | 2.87 | NA | 3.11 | NA |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.28 | NA | -0.21 | NA |
Diluted Net EPS (GAAP) | -0.31 | -0.28 | -0.38 | -0.21 | -0.32 |